Lightlake Therapeutics Receives Milestone Payment for Nasal Spray
Lightlake Therapeutics Inc. recently announced it has received a $2-million milestone payment from Adapt Pharma Limited. This milestone payment was triggered by the US FDA approval of NARCAN (naloxone hydrochloride) Nasal Spray for the emergency treatment of known or suspected opioid overdose, to be marketed by Adapt, Lightlake’s commercial partner. The FDA approved NARCAN Nasal Spray on November 18, 2015. Lightlake also expects to receive a $2.5-million milestone payment from Adapt after the prospective first commercial sale of NARCAN Nasal Spray in the US.
“We are extremely pleased with our relationship with our partner Adapt and impressed by their investment and commercial efforts with respect to NARCAN Nasal Spray,” said Kevin Pollack, CFO of Lightlake. “We plan to use this FDA approval milestone payment to progress Lightlake’s operational and research and development activities.”
In December 2014, Lightlake announced a licensing deal with Adapt. As per the terms of the deal, in exchange for licensing its opioid overdose reversal treatment, Lightlake could receive potential development and sales milestone payments of more than $55 million, plus up to double-digit percentage royalties on net sales.
Lightlake plans now to focus on developing products for substance abuse, addictions, and eating disorders. Over the next year, Lightlake plans to bring its next generation of products into clinical trials.
Lightlake Therapeutics Inc. is a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive, and eating disorders. Lightlake has entered into a licensing deal with a subsidiary of Adapt Pharma Limited with respect to a treatment to reverse opioid overdoses, which have reached epidemic proportions in the US. This treatment, NARCAN Nasal Spray, was approved by the US FDA in November 2015. Lightlake also has collaborated on clinical trials with the National Institute on Drug Abuse, part of the National Institutes of Health, with respect to this treatment. In addition, Lightlake has completed a Phase II clinical trial to treat Binge Eating Disorder. For more information, visit www.lightlaketherapeutics.com.
Total Page Views: 1209
